Article

T-lymphocyte-antigen interactions in transplant rejection.

Department of Pediatrics, Stanford University School of Medicine, Calif.
New England Journal of Medicine (Impact Factor: 54.42). 03/1990; 322(8):510-7. DOI: 10.1056/NEJM199002223220805
Source: PubMed
0 Bookmarks
 · 
215 Views
  • Source
    Samter’s Immunologic Diseases, Sixth Edition edited by K Frank Austen, Michael M Frank, John P Atkinson, Harvey Cantor, 01/2001: chapter 84: pages 1121-32; Lippincott Williams & Wilkins., ISBN: 0-7817-2120-2
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The discovery of induced pluripotent stem cells (iPSCs) and concurrent development of protocols for their cell-type specific differentiation have revolutionized studies of diseases and raised the possibility that personalized medicine may be achievable. Realizing the full potential of iPSC will require addressing the challenges inherent in obtaining appropriate cells for millions of individuals while meeting the regulatory requirements of delivering therapy and keeping costs affordable. Critical to making PSC based cell therapy widely accessible is determining which mode of cell collection, storage and distribution, will work. In this manuscript we suggest that moderate sized bank where a diverse set of lines carrying different combinations of commonly present HLA alleles are banked and differentiated cells are made available to matched recipients as need dictates may be a solution. We discuss the issues related to developing such a bank and how it could be constructed and propose a bank of selected HLA phenotypes from carefully screened healthy individuals as a solution to delivering personalized medicine.
    Stem Cell Reviews and Reports 12/2014; 11(1). DOI:10.1007/s12015-014-9574-4 · 3.21 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prevention of Graft-versus-Host-Disease (GvHD) by preserved Graft-versus-Leukaemia (GvL) effect is one of the major obstacles following allogeneic haematopoietic stem cell transplantation. Currently used drugs are associated with side effects and were not able to separate GvHD from the GvL-effect because of general T-cell suppression. This review focuses on murine models for GvHD and currently available treatment options involving antibodies and applications for the therapeutic use of aptamers as well as strategies for targeting immune responses by allogenic antigens.
    Journal of Cellular and Molecular Medicine 10/2014; DOI:10.1111/jcmm.12416 · 3.70 Impact Factor